The incidence of Metabolic Syndrome (MetS) has risen globally. MetS includes a combination of features, i.e. blood glucose impairment, excess abdominal/body fat dyslipidemia and elevated blood pressure. Other than conventional treatment with drugs, the main preventive approaches include lifestyle changes, weight loss, diet control and adequate exercise also proves to be beneficial. MicroRNAs (miRNAs) are small non-coding RNAs that play critical regulatory roles in most biological and pathological processes. In the present review, we discuss various miRNAs which are related to MetS by targeting various organs, including the pancreas, liver, skeletal muscles and adipose tissues. These miRNAs have the effect on insulin production and secretion (miR-9, miR-124a, miR-130a,b, miR152, miR-335, miR-375), insulin resistance (miR-29), adipogenesis (miR-143, miR148a) and lipid metabolism (miR-192). We also discuss the miRNAs as potential biomarkers and future therapeutic targets. This review may be beneficial for molecular biologists and clinicians dealing with MetS.

中文翻译：

---

微型RNA和代谢综合征的特征：叙事回顾。

全球代谢综合征（MetS）的发病率上升。MetS具有多种功能的组合，例如血糖受损，腹部/身体脂肪过多血脂异常和血压升高。除了常规的药物治疗外，主要的预防方法包括改变生活方式，减轻体重，控制饮食和适当的运动，也被证明是有益的。微小RNA（miRNA）是小的非编码RNA，在大多数生物学和病理过程中都起着关键的调节作用。在本综述中，我们讨论了通过靶向各种器官（包括胰腺，肝脏，骨骼肌和脂肪组织）与MetS相关的各种miRNA。这些miRNA可影响胰岛素的产生和分泌（miR-9，miR-124a，miR-130a，b，miR152，miR-335，miR-375），胰岛素抵抗（miR-29），脂肪形成（miR-143，miR148a）和脂质代谢（miR-192）。我们还将讨论miRNA作为潜在的生物标志物和未来的治疗目标。这项审查可能对处理MetS的分子生物学家和临床医生有益。